Genfit Unveils New Clinical Trials and Strategic Milestones for 2025

On February 6, 2025, Genfit, a biopharmaceutical company dedicated to addressing liver diseases, announced a series of new clinical trials and critical milestones aimed at advancing its research and development pipeline.

These initiatives reflect the company’s commitment to innovation in the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic conditions.

The company revealed plans to commence Phase 3 clinical trials for its leading drug candidate, elafibranor, which has shown promising results in earlier studies for improving liver health and reducing fibrosis.

Genfit’s Chief Executive Officer, Pascal Prigent, emphasized the significance of this milestone, stating, “We are excited to move forward with our Phase 3 trials, as they represent a pivotal step toward bringing effective treatments to patients suffering from NASH.”

In addition to the new trials, Genfit outlined key strategic partnerships established over the past year, aimed at enhancing its research capabilities and broadening its market reach.

The collaborations with academic institutions and industry leaders are expected to facilitate the development of innovative therapies and accelerate the commercialization process.

As Genfit progresses through 2025, the company remains focused on its mission to provide solutions for unmet medical needs in liver diseases, with the hope of ultimately improving patient outcomes worldwide.